NCAM1 and glioblastoma: As illustrated in Supplementary Figure 4A (CD3-/CD94+) and Figure 4B (CD3-/CD56+) glioblastoma patients with higher NK cell counts (>5% and >7.5%, respectively) have a trend toward a more favorable progression-free survival—which also reflects the OS in glioblastoma patients—than patients with lower NK cell counts (p = 0.05).